Malignant Esophageal Neoplasm — Trials

Malignant Esophageal Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,926 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 518
Recruiting: 301
Ph III recruiting: 41
Growth YoY: +4.1%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 28.5%
Trials / 1,000 deaths: 32.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (169)

clinicaltrialsPublishedShowing 1–9 of 9 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05152147	A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers(HERIZON-GEA-01)	active not recruiting	Phase 3	920	Jazz PharmaceuticalsINDUSTRY	33	Sep 24, 2026	clinicaltrials
NCT05043688	Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.	active not recruiting	Phase 3	426	Zhigang LiOTHER	1	Sep 17, 2026